In an article by MacLennan et al (Eur Urol 61 (2012) 972-993) 4580 abstracts and 389 full text articles were assessed. The evidence base suggests that localised renal clear cell carcinoma <4cms is best managed by nephron sparing rather than radical surgery where technically feasible. Results for tumours >4cms are equivalent. Open and laparoscopic surgery achieved equivalent survival.

In an article by Oelke (Eur Urol 61 (2012) 917-915) mono therapy with Tamsulosin or Tadalafil resulted in significant and numerically similar improvements in LUTS, but only Tadalafil improved ED. However, the study was not powered to directly compare these agents. A systematic review by Gacci et al (Eur Urol 61(2012) 994-1003) assessed 107 articles suggests PDE5I can significantly improve LUTS.

4383 men were followed for 28 years in a study Orsted et al from Denmark (Eur Urol 61(2012) 865-874). Patients with a baseline PSA under 1ng/ml had a very low risk of future prostate cancer diagnosis and mortality. Indeed, an editorial suggested that if PSA<2 and age>64, no further screening is required and if age <65 PSA screening may not need to be repeated for 10 years. If PSA=2-4 then a further PSA screen could be left for 2-4 years. A PSA>4 required a detailed examination for prostate cancer.